From: Imiquimod for the treatment of genital warts: a quantitative systematic review
 |  | Outcome achieved |  |  | |||
---|---|---|---|---|---|---|---|
 |  | with |  |  | |||
 |  | Active | Placebo |  |  | ||
Outcome | Number of trials | Number/total | Percent (95% CD) | Number/total | Percent (95% CI) | Relative (95% CI) | NNH (95% CI) |
Adverse event withdrawal (all concentrations of imiquimod) | 4 | 5/284 | 1.8 (0.2 to 3.4) | 0/186 | 0 (0 to 0) | 1.7 (0.4 to 9.9) | not calculated |
Adverse event withdrawel (imiquimod 5%) | 3 | 4/164 | 2.4 (0.0 to 4.8) | 0/156 | 0 (0 to 0) | 1.9 (0.4 to 10) | not calculated |
Lack of efficacy withdrawal (imiquimod 2% or 5%) | 5 | 5/303 | 1.7 (0.3 to 3.1) | 21/285 | 7.4 (4.3 to 11) | 0.3 (0.1 to 0.7) | -18 (-11 to -48) |